Register Login
Register to leave comments
  • News bot April 30, 2026, 11:11 a.m.

    📋 KYMERA THERAPEUTICS, INC. (KYMR) - Financial Results

    Filing Date: 2026-04-30

    Accepted: 2026-04-30 07:10:15

    Event Type: Financial Results

    Event Details:

    KYMERA THERAPEUTICS, INC. (KYMR) Reports the reporting period Financial Results KYMERA THERAPEUTICS, INC. (KYMR) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: $ 34,365
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: $ 1,545,653
      • 579 through clinical development, our focus remains on disciplined execution and delivering on multiple important milestones this year,” said Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics. “We remain committed to translating our first
      • class science into better outcomes for patients. Our STAT6 and IRF5 oral degrader programs exemplify this mission, and the growing recognition of our work within the scientific and medical community further validates the potential of our approach. We are continuing to build on this foundation with the advancement of KT
      • 200, our oral CDK2 molecular glue degrader partnered with Gilead, and through progress within our early
        • expected by mid-2027
        • expected in 2026
        • expected in 2H26 Gilead Sciences exercised its option to exclusively license KT-200, a first-in-class, oral CDK2 molecular glue degrader, generating a $45 million milestone, with IND planned in 2027

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2026 2025 Change ($) Change (%)
    Assets Cash Equivalents Marketable Securities 1.55M 1.62M $-73.78K -4.56%
    Assets Property Equipment Net 41.62K 43.17K $-1.56K -3.61%
    Assets Other Assets 40.01K 37.85K $2.16K +5.70%
    Liabilities And Stockholders Equity Operating Lease Liabilities 77.62K 78.97K $-1.36K -1.72%
    Operating Expenses Loss From Operations -84.15K -74.43K $-9.73K -13.07%
    Cash and Marketable Securities 1.55M 1.55M $0.00 +0.00%
    Property and Equipment, Net 41.62K 41.62K $0.00 +0.00%
    Other Assets 40.01K 40.01K $0.00 +0.00%
    Operating Lease Liabilities 77.62K 77.62K $0.00 +0.00%
    Revenue 34.37K 22.10K $12.27K +55.50%
    Loss from Operations -84.15K -74.43K $-9.73K -13.07%
    Net Loss 69.23K 65.58K $3.65K +5.57%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: KYMERA THERAPEUTICS, INC.
    • Ticker Symbol: KYMR

Search

News categories